A Phase 1, First in Human, Dose-Escalation Study of TORL-3-600 in Participants with Advanced Cancer
NCT #
NCT05948826
Condition(s)
Colorectal Cancer
Molecular Target(s)
CDH17
Drug Classification(s)
Antibody Drug Conjugate
Agents(s)
TORL-3-600
Phase(s)
I
Mechanism of Action
TORL-3-600 is a CDH(/cadherin)17 targeting ADC
Purpose
- How much of the study agent can be given with an acceptable level of side effects
- The effects of the study agent (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.